Patents by Inventor Neil Lajkiewicz

Neil Lajkiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds as immunomodulators
    Patent number: 11866435
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: January 9, 2024
    Assignee: Incyte Corporation
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 11713317
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: August 1, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230226062
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 26, 2022
    Publication date: July 20, 2023
    Inventors: Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230100875
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 30, 2023
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11535615
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: December 27, 2022
    Assignee: Incyte Corporation
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • Tricyclic amine compounds as CDK2 inhibitors
    Patent number: 11440914
    Abstract: The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 13, 2022
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Neil Lajkiewicz, Ken Mukai, Liangxing Wu, Wenqing Yao
  • Heteroaryl amide compounds as sting activators
    Patent number: 11427597
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: August 30, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220213090
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 24, 2021
    Publication date: July 7, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Chunhong He, Kaijiong Xiao, Wenyu Zhu, Zhenwu Li, Song Mei, Chao Qi, Leah C. Konkol, Wenqing Yao
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS
    Publication number: 20220073509
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: March 2, 2021
    Publication date: March 10, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS
    Publication number: 20220056049
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: January 6, 2020
    Publication date: February 24, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS
    Publication number: 20210163493
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 3, 2021
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 10947227
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 16, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20200407357
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • Heteroaryl amide compounds as sting activators
    Patent number: 10875872
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: December 29, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20200347067
    Abstract: The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: April 30, 2020
    Publication date: November 5, 2020
    Inventors: Qinda Ye, Neil Lajkiewicz, Ken Mukai, Liangxing Wu, Wenqing Yao
  • Imidazopyridines and imidazopyrazines as LSD1 inhibitors
    Patent number: 10640503
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS
    Publication number: 20200039994
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS
    Publication number: 20190359608
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 28, 2019
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20190040058
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: July 18, 2018
    Publication date: February 7, 2019
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Aglaroxin C and derivatives as HCV entry inhibitors
    Patent number: 10085988
    Abstract: A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: October 2, 2018
    Assignees: SRI International, Trustees of Boston University
    Inventors: Tony Tianyi Wang, Shufeng Liu, Wenyu Wang, Neil Lajkiewicz, John A. Porco, Jr.